Guido Neels Purchases 20,000 Shares of Elutia (NASDAQ:ELUT) Stock

Elutia Inc. (NASDAQ:ELUT) Director Guido Neels acquired 20,000 shares of the company’s stock in a transaction dated Friday, January 30th. The shares were acquired at an average cost of $1.04 per share, with a total value of $20,800.00. Following the completion of the purchase, the director owned 118,750 shares in the company, valued at approximately $123,500. This represents a 20.25% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Elutia Price Performance

NASDAQ:ELUT traded down $0.00 during trading hours on Monday, reaching $1.05. 84,912 shares of the company traded hands, compared to its average volume of 371,448. The firm’s 50-day moving average is $0.71 and its 200-day moving average is $1.16. The stock has a market cap of $44.83 million, a P/E ratio of -1.14 and a beta of 0.67. Elutia Inc. has a 1-year low of $0.50 and a 1-year high of $3.46.

Elutia (NASDAQ:ELUT) last issued its quarterly earnings data on Thursday, November 6th. The company reported ($0.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.15. The company had revenue of $3.32 million during the quarter, compared to analysts’ expectations of $6.65 million. As a group, research analysts predict that Elutia Inc. will post -1.74 earnings per share for the current year.

Hedge Funds Weigh In On Elutia

Several institutional investors and hedge funds have recently bought and sold shares of ELUT. Arcus Capital Partners LLC boosted its holdings in Elutia by 50.3% in the 2nd quarter. Arcus Capital Partners LLC now owns 30,050 shares of the company’s stock worth $59,000 after acquiring an additional 10,050 shares during the period. XTX Topco Ltd purchased a new stake in shares of Elutia during the second quarter valued at approximately $28,000. Jane Street Group LLC acquired a new position in shares of Elutia during the first quarter worth $48,000. Virtu Financial LLC purchased a new position in shares of Elutia in the third quarter valued at $26,000. Finally, FNY Investment Advisers LLC acquired a new stake in Elutia during the 4th quarter valued at $25,000. Institutional investors and hedge funds own 74.03% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on ELUT. Wall Street Zen upgraded shares of Elutia to a “sell” rating in a research report on Saturday, November 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of Elutia in a research note on Wednesday, January 21st. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $7.00.

About Elutia

Elutia, Inc is a biopharmaceutical company focused on the development of novel nitric oxide therapies based on its proprietary polymeric nitric oxide platform. This technology is designed to enable sustained, controlled release of nitric oxide to targeted tissues, potentially overcoming the delivery challenges associated with gaseous nitric oxide and small?molecule donors.

The company’s lead program is in preclinical development for pulmonary arterial hypertension, with additional research efforts aimed at other cardiovascular and respiratory conditions.